Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Deborah Hibbett, Senior Vice President, Head of Global Corporate Affairs and Sustainability, Plasma-Derived Therapies at Takeda, shared on LinkedIn:
”The updated European Medicines Agency’s Union List of Critical Medicines now includes a plasma-derived therapy for hemophilia patients with inhibitors.
This addition underscores that reliable, uninterrupted access to critical medicines – including this product and the other listed plasma-derived therapies – is essential for patients, families and healthcare systems.
Takeda celebrates this update as we are also committed to the bleeding disorders community and to creating value through sustainable, equitable access – including our renewed collaboration with the WFH Humanitarian Aid Program and the work highlighted in Takeda’s 2025 Access to Medicines Update.
Thank you to the healthcare community, patient advocates and partners who continue to advance security of supply and equity in care every day.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients